Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Inc.

www.pfizer.com

Latest From Pfizer Inc.

Latecomer Alunbrig Faces Entrenched Rivals After US 1L Approval

First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.

United States Approvals

Sales Of Injectable CBD Offered OTC In US Stop With Recall; ChapStick, Benefiber Also Recalled

Recent US consumer health and beauty product recalls also include three shades of lip moisturizer with sunscreen, made by Pfizer and marketed by GSK due to a packaging problem. A Florida firm recalled one lot of a CBD oil tincture after a state agency’s test found high lead levels.

Cannabidiol CBD Recalls

Finance Watch: Atea Pharmaceuticals Raises $215m For COVID-19 Antiviral

Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.

Financing Coronavirus COVID-19

SELECTION Positive For Gilead/Galapagos’s Filotinib In UC But Will It Be Enough To Compete?

Gilead and Galapagos’s closely watched JAK inhibitor filgotinib has produced some promising Phase IIb/III data in ulcerative colitis. The question now is whether they will be enough to allow the product to put in a strong showing in this competitive market.

Clinical Trials Companies
See All

Company Information

UsernamePublicRestriction

Register